Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Betrixaban Formulations
NCT02596100Phase 1Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of betrixaban in venous thromboembolism (VTE) (2 arms), sponsored by Portola Pharmaceuticals. Primary endpoints: Total Area Under the Curve at 120 hours and Peak Plasma Concentration at 120 hours. Started Sep 2015; status: completed.
02
Drugs
betrixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02596100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596100.